OncoMatch/Clinical Trials/NCT06207305
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
Is NCT06207305 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Dexamethasone and Famotidine for metastatic appendiceal adenocarcinoma.
Treatment: Dexamethasone · Diphenhydramine · Famotidine · Paclitaxel — To find the recommended dose of the drug paclitaxel that can be given intraperitoneally (given directly into the abdominal cavity) to participants with metastatic appendiceal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
leukocytes ≥3000/mcl, absolute neutrophil count ≥1,500/mcl, platelets ≥75,000/mcl
Kidney function
creatinine ≤ 1.5x institutional uln
Liver function
total bilirubin ≤ institutional upper limit of normal (uln)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06207305 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify